We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 11, 2021

Safety and Efficacy of 7 Days on/7 Days off vs 14 Days on/7 Days off Schedules of Capecitabine in Patients With Metastatic Colorectal Cancer

Clinical Colorectal Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Colorectal Cancer
Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients With Metastatic Colorectal Cancer: A Retrospective Review
Clin Colorectal Cancer 2021 Mar 16;[EPub Ahead of Print], E Bryson, E Sakach, U Patel, M Watson, K Hall, A Draper, C Davis, S Goyal, O Alese, M Akce, W Shaib, B El-Rayes, S Szabo, C Wu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading